Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NIM811
- Development stage
- Phase 2
- Lead developer
- Novartis
- Modality
- Cyclic Peptides → Modified Peptides → Peptides, Small Molecules, Recombinant Proteins and Enzymes
- Administration
- Oral
01
Overview
NIM811 is a non-immunosuppressive cyclosporine analog and a potent dual inhibitor of mitochondrial permeability transition and cyclophilin. Unlike cyclosporine A, the binary complex of NIM811 with cyclophilin cannot bind to calcineurin and therefore does not exhibit immunosuppressive activity[2][7]. It has demonstrated in vitro antiviral activity against hepatitis C virus (HCV), with clinical studies exploring its use for chronic hepatitis C infection[3][5]. Additionally, it is being investigated as a potential treatment for genetic muscular diseases such as Ullrich congenital muscular dystrophy (UCMD) and Bethlem myopathy (BM)[2][7].
- Other names
- (Melle-4)cyclosporin9-(N-methyl-L-isoleucine)-cyclosporin A9-(N-methylisoleucine)cyclosporin A
02
Targets
PPIA (Peptidyl-prolyl cis-trans isomerase A)PPIF (Cyclophilin D)Cyp (Cyclophilin family)MPTP (Mitochondrial permeability transition pore)
Beyond the preview
Go deeper on NIM811.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NIM811.